Engineered immune cells take on Hard-to-Treat cancers
Disease control
Not yet recruiting
This early-phase study tests a new treatment using specially engineered natural killer (NK) cells boosted with IL-15 to fight advanced solid tumors that have not responded to standard therapies. About 12 adults aged 18-70 with metastatic or recurrent cancers like breast, liver, o…
Phase: EARLY_PHASE1 • Sponsor: Genovn Therapeutics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Jun 16, 2026 12:50 UTC